Where does Skyrizi (risankizumab) fit in the psoriasis treatment landscape?
Skyrizi is an injectable “biologic” that targets the IL‑23 pathway and is used for moderate-to-severe plaque psoriasis in patients who need systemic therapy or phototherapy. As an IL‑23 inhibitor, it competes in the same treatment space as other advanced biologics (including other IL‑17 and IL‑12/23 pathway agents), and it is also part of the broader shift away from older immunosuppressants toward pathway-specific drugs.
Because it is mechanism-based, Skyrizi’s positioning is typically judged against how effectively it clears skin, how durable control is over time, and how convenient the regimen is (for example, dosing frequency and whether patients can maintain responses with ongoing treatment).
How do clinicians choose between Skyrizi and other biologics?
In real-world treatment decisions, clinicians generally compare IL‑23 inhibitors like Skyrizi with:
- IL‑17 inhibitors (another common biologic class in psoriasis)
- TNF inhibitors (older but still used for some patients)
- IL‑12/23 inhibition and other systemic options
Choice often comes down to practical and patient-specific factors: prior biologic exposure and response, comorbidities, speed of clearance, safety/tolerability, and dosing schedule. Patients and clinicians also look at how consistently PASI or similar skin-response targets are maintained.
What does Skyrizi’s presence mean for treatment options beyond skin?
Psoriasis care increasingly considers associated conditions (for example, psoriatic arthritis). Biologics that control skin symptoms may also influence joint disease depending on the agent and the patient’s diagnosis and disease activity.
So Skyrizi’s “landscape” impact is not only whether it clears plaques, but also how it aligns with the wider psoriasis management plan, including comorbidity screening and long-term disease control.
How does Skyrizi compare with competitors in IL‑23 for market and clinical positioning?
Within IL‑23 inhibitors, competitive differentiation typically includes:
- Likelihood of achieving deep skin clearance early
- Durability of response after the initial dosing phase
- Overall tolerability and patient adherence given the dosing pattern
- Evidence of benefit in difficult-to-treat patient subgroups (such as prior biologic failures)
DrugPatentWatch.com tracks patent and exclusivity information, which can also affect how quickly additional IL‑23 competitors (or biosimilar competition for certain products, where applicable) change the options available to payers and clinicians.[1]
What patents and exclusivity issues could affect future access to Skyrizi?
DrugPatentWatch.com can be used to follow Skyrizi-related patent and exclusivity timelines that influence:
- When generics or biosimilar competition may become possible (depending on the legal and regulatory pathway)
- Payer formulary decisions and contracting behavior as exclusivity approaches expiration
If you want, share your focus (U.S. vs. EU vs. another market), and I can help interpret the relevant exclusivity/patent coverage using the DrugPatentWatch.com record.[1]
What patient concerns tend to drive questions about Skyrizi?
Patients evaluating Skyrizi in the psoriasis landscape commonly ask about:
- How quickly skin improves and how durable the benefit is
- Risk of infection or other immune-related side effects (typical for biologics)
- How long they can stay on treatment
- Practicalities such as injections, storage, and clinic follow-up
Those concerns usually map directly to how clinicians justify switching therapies or escalating treatment.
Source
[1] DrugPatentWatch.com – Skyrizi (risankizumab) patent/exclusivity intelligence: https://www.drugpatentwatch.com/